Clemence Dehillotte
Overview
Explore the profile of Clemence Dehillotte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guyot E, Reynaud Q, Belhassen M, Berard M, Dehillotte C, Lemonnier L, et al.
J Cyst Fibros
. 2024 Mar;
23(5):903-909.
PMID: 38480112
Background: We studied the health care resource utilization (HCRU) and associated costs in the year preceding LT in pwCF or death without LT, and we estimated the overall cost of...
2.
Orenti A, Pranke I, Faucon C, Varilh J, Hatton A, Golec A, et al.
J Cyst Fibros
. 2023 Jul;
22(6):1070-1079.
PMID: 37422433
Rationale: Limited information is available on the clinical status of people with Cystic Fibrosis (pwCF) carrying 2 nonsense mutations (PTC/PTC). The main objective of this study was to compare disease...
3.
Andrejak C, Priou P, Richaud-Thiriez B, Macey J, Montcouquiol S, Douvry B, et al.
Eur Respir J
. 2023 Feb;
61(5.
PMID: 36796836
Background: The European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (CF) carrying at least one F508del variant....
4.
Rousset-Jablonski C, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Jacoud F, et al.
Front Public Health
. 2022 Dec;
10:1043691.
PMID: 36483264
Background: Cystic fibrosis (CF) care and the life expectancy of affected patients have substantially improved in recent decades, leading to an increased number of patients being diagnosed with comorbidities, including...
5.
Coriati A, Ma X, Sykes J, Stanojevic S, Ruseckaite R, Lemonnier L, et al.
Thorax
. 2022 Sep;
78(3):242-248.
PMID: 36109163
Background: Life expectancy for people with cystic fibrosis (CF) varies considerably both within and between countries. The objective of this study was to compare survival among countries with single-payer healthcare...
6.
Corvol H, de Miranda S, Dehillotte C, Lemonnier L, Chiron R, Danner-Boucher I, et al.
Clin Infect Dis
. 2022 Apr;
75(12):2135-2144.
PMID: 35475917
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are closely monitored in people with cystic fibrosis (pwCF), especially severe cases. Previous studies used hospitalization rates as proxy for severity....
7.
Coriati A, Sykes J, Lemonnier L, Ma X, Stanojevic S, Dehillotte C, et al.
Eur Respir J
. 2021 Jun;
59(1).
PMID: 34140297
Background: France implemented a high emergency lung transplantation (HELT) programme nationally in 2007. A similar programme does not exist in Canada. The objectives of our study were to compare health...
8.
Durieu I, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Berard M, et al.
J Cyst Fibros
. 2021 Apr;
21(1):88-95.
PMID: 33865726
Background: Better insights into the natural course of cystic fibrosis (CF) have led to treatment approaches that have improved pulmonary health and increased the life expectancy of affected individuals. This...
9.
Burgel P, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, et al.
J Cyst Fibros
. 2020 Jun;
20(2):220-227.
PMID: 32591294
Background: Phase 3 trials have demonstrated the safety and efficacy of lumacaftor-ivacaftor (LUMA-IVA) in patients with cystic fibrosis (CF) homozygous for the Phe508del CFTR mutation and percent predicted forced expiratory...
10.
Burgel P, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al.
Am J Respir Crit Care Med
. 2019 Oct;
201(2):188-197.
PMID: 31601120
Lumacaftor-ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation. To evaluate the safety and effectiveness...